Digital exercise program with live virtual group sessions for men on hormone therapy during radiotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-centre phase III randomized controlled trial randomises men with histologically confirmed prostate adenocarcinoma who are starting or within eight weeks of LHRHa androgen deprivation therapy and planned for radiotherapy to a digital exercise programme with virtual supervised group sessions or to usual care. The intervention is delivered via the MyMarsden platform and requires a device for video conferencing to join live group exercise sessions and follow structured workouts remotely. The primary focus is improving adherence to recommended physical activity, with secondary measures including body composition, fatigue, cardiovascular risk markers and quality of life. Participants must be assessed safe to exercise, be English-fluent, and not be planned for ARTA or chemotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age \> 18 at randomisation
2. Men with histological confirmation of prostate adenocarcinoma who are receiving or planned to receive ADT with an LHRHa as part of their PCa treatment
3. If already started ADT, have received no more than eight weeks ADT at randomisation
4. Planned for radiotherapy
5. Assessed by clinical team to be safe to exercise and safe to enter the trial with no absolute contraindications to exercise as defined by clinical guidance
6. Able to use technological aspects of the intervention including access to MyMarsden and a device for video conferencing
7. Fluent in English and able to understand instructions
8. WHO performance status 0-2
9. Able to give written informed consent

Exclusion Criteria:

1. Men planned to receive an androgen receptor-targeted agent (ARTA) or chemotherapy
2. Absolute contraindication to exercise as defined by ACPICR standards. This includes:

   * New symptoms of angina
   * New or unstable heart failure
   * Newly diagnosed diabetes that is not controlled
   * New or untreated arrhythmias
   * Resting tachycardia or new bradycardia (not linked to changes in medications)
   * Symptomatic hypotension
   * Uncontrolled hypertension (SBP ≥ 180mmHg or DBP≥ 100mmHg)
3. Unstable spinal bone metastasis or at high risk of a fracture
4. Musculoskeletal issue inhibiting exercise

Where it's running

• The Royal Marsden Hospital
  London, United Kingdom Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using new non-contrast MRI sequences to improve diagnosis and grading of prostate cancer

  This project tries new non-contrast MRI scans to see if they improve diagnosis and grading for men with suspected prostate cancer and elevated PSA.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07552285

• Epidemiology, diagnosis, and treatment patterns of prostate cancer in Algeria

  This project collects medical and treatment information to see how prostate cancer is diagnosed and managed in Algerian men with confirmed disease.

  Recruiting at 21 sites Société Algérienne de Formation et Recherche en Oncologie · Adrar, Algeria and 23 other locations · NCT07484971

• PROSTest test in men with elevated PSA to aid prostate cancer decisions

  This study tests PROSTest in men with elevated PSA to see if it can accurately detect prostate cancer using biopsy results as the reference.

  Recruiting Wren Laboratories LLC · Branford, Connecticut · NCT07454603

• MRI- and PHI-guided approach to decide when a prostate biopsy is needed

  This trial will test whether using multiparametric MRI together with the Prostate Health Index (PHI) can safely reduce unnecessary prostate biopsies in biopsy-naïve men with suspected prostate cancer and PSA 3–20 ng/mL.

  Recruiting Asan Medical Center · Seoul · NCT07398690

• Comparing Lutetium-177 and Actinium-225 PSMA-targeted radiation before prostatectomy

  This will test whether giving one of two PSMA-targeted radiation drugs (Lutetium-177 or Actinium-225) before prostate removal works differently in men with high or very high-risk localized prostate cancer.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07054346

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.